Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN) (DBCOND0039701)

Identifiers

Synonyms

Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Cetuximab	An endothelial growth factor receptor binding fragment used to treat colorectal cancer as well as squamous cell carcinoma of the head and neck.	Epidermal growth factor receptortarget Low affinity immunoglobulin gamma Fc region receptor III-Btarget Complement C1q subcomponent subunit Atarget Complement C1q subcomponent subunit Btarget Complement C1q subcomponent subunit Ctarget Low affinity immunoglobulin gamma Fc region receptor III-Atarget High affinity immunoglobulin gamma Fc receptor Itarget Low affinity immunoglobulin gamma Fc region receptor II-atarget
Hydroxyurea	An antimetabolite used to treat sickle cell anemia crisis, resistant chronic myeloid leukemia, and Locally advanced squamous cell carcinomas of the head and neck (excluding the lip).	Ribonucleoside-diphosphate reductase large subunittarget Solute carrier organic anion transporter family member 1A2transporter Solute carrier organic anion transporter family member 1B1transporter Solute carrier organic anion transporter family member 1B3transporter Urea transporter 2transporter Urea transporter 1transporter Solute carrier family 22 member 4transporter Organic cation/carnitine transporter 2transporter Albumincarrier Urease subunit alphaenzyme Ribonucleoside-diphosphate reductase subunit M2target

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT03452137	A Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck	Atezolizumab	treatment	3	terminated
NCT00627835	Dose Escalation Trial of Neoadjuvant Sorafenib and Concurrent Sorafenib, Cisplatin and Radiation in Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN)	Cisplatin Sorafenib	Not Available	1	withdrawn